Louisa M S Gerhardt1, Maren Kordsmeyer2,3, Susanne Sehner4, Gülmisal Güder2,5, Stefan Störk2,5, Frank Edelmann6, Rolf Wachter7, Sabine Pankuweit8, Christiane Prettin9, Georg Ertl2, Christoph Wanner2,10, Christiane E Angermann11. 1. Department of Stem Cell Biology and Regenerative Medicine, Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA. 2. Comprehensive Heart Failure Centre, University and University Hospital Würzburg, Am Schwarzenberg 15, 97078, Würzburg, Germany. 3. Department of Medicine I, St Josefs-Hospital Wiesbaden, Wiesbaden, Germany. 4. Medical Centre Hamburg-Eppendorf, Institute of Medical Biometry and Epidemiology, Hamburg, Germany. 5. Department of Medicine I, University Hospital Würzburg, Würzburg, Germany. 6. Department of Internal Medicine, Cardiology, Charité - Campus Virchow Klinikum, Universitätsmedizin Berlin, and German Centre for Cardiovascular Research, Partner Site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany. 7. Clinic and Policlinic for Cardiology and Pneumology, University Hospital Leipzig, Leipzig, Germany. 8. Department of Cardiology, Philips-University Marburg, Marburg, Germany. 9. Clinical Trial Centre Leipzig, University of Leipzig, Leipzig, Germany. 10. Department of Medicine I (Nephrology), University Hospital Würzburg, Würzburg, Germany. 11. Comprehensive Heart Failure Centre, University and University Hospital Würzburg, Am Schwarzenberg 15, 97078, Würzburg, Germany. Angermann_c@ukw.de.
Abstract
BACKGROUND: The importance of chronic kidney disease (CKD) and anaemia has not been comprehensively studied in asymptomatic patients at risk for heart failure (HF) versus those with symptomatic HF. We analysed the prevalence, characteristics and prognostic impact of both conditions across American College of Cardiology/American Heart Association (ACC/AHA) precursor and HF stages A-D. METHODS AND RESULTS: 2496 participants from three non-pharmacological German Competence Network HF studies were categorized by ACC/AHA stage; stage C patients were subdivided into C1 and C2 (corresponding to NYHA classes I/II and III, respectively). Overall, patient distribution was 8.1%/35.3%/32.9% and 23.7% in ACC/AHA stages A/B/C1 and C2/D, respectively. These subgroups were stratified by the absence ( - ) or presence ( +) of CKD (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73m2) and anaemia (haemoglobin in women/men < 12/ < 13 g/dL). The primary outcome was all-cause mortality at 5-year follow-up. Prevalence increased across stages A/B/C1 and C2/D (CKD: 22.3%/23.6%/31.6%/54.7%; anaemia: 3.0%/7.9%/21.7%/33.2%, respectively), with concordant decreases in median eGFR and haemoglobin (all p < 0.001). Across all stages, hazard ratios [95% confidence intervals] for all-cause mortality were 2.1 [1.8-2.6] for CKD + , 1.7 [1.4-2.0] for anaemia, and 3.6 [2.9-4.6] for CKD + /anaemia + (all p < 0.001). Population attributable fractions (PAFs) for 5-year mortality related to CKD and/or anaemia were similar across stages A/B, C1 and C2/D (up to 33.4%, 30.8% and 34.7%, respectively). CONCLUSIONS: Prevalence and severity of CKD and anaemia increased across ACC/AHA stages. Both conditions were individually and additively associated with increased 5-year mortality risk, with similar PAFs in asymptomatic patients and those with symptomatic HF.
BACKGROUND: The importance of chronic kidney disease (CKD) and anaemia has not been comprehensively studied in asymptomatic patients at risk for heart failure (HF) versus those with symptomatic HF. We analysed the prevalence, characteristics and prognostic impact of both conditions across American College of Cardiology/American Heart Association (ACC/AHA) precursor and HF stages A-D. METHODS AND RESULTS: 2496 participants from three non-pharmacological German Competence Network HF studies were categorized by ACC/AHA stage; stage C patients were subdivided into C1 and C2 (corresponding to NYHA classes I/II and III, respectively). Overall, patient distribution was 8.1%/35.3%/32.9% and 23.7% in ACC/AHA stages A/B/C1 and C2/D, respectively. These subgroups were stratified by the absence ( - ) or presence ( +) of CKD (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73m2) and anaemia (haemoglobin in women/men < 12/ < 13 g/dL). The primary outcome was all-cause mortality at 5-year follow-up. Prevalence increased across stages A/B/C1 and C2/D (CKD: 22.3%/23.6%/31.6%/54.7%; anaemia: 3.0%/7.9%/21.7%/33.2%, respectively), with concordant decreases in median eGFR and haemoglobin (all p < 0.001). Across all stages, hazard ratios [95% confidence intervals] for all-cause mortality were 2.1 [1.8-2.6] for CKD + , 1.7 [1.4-2.0] for anaemia, and 3.6 [2.9-4.6] for CKD + /anaemia + (all p < 0.001). Population attributable fractions (PAFs) for 5-year mortality related to CKD and/or anaemia were similar across stages A/B, C1 and C2/D (up to 33.4%, 30.8% and 34.7%, respectively). CONCLUSIONS: Prevalence and severity of CKD and anaemia increased across ACC/AHA stages. Both conditions were individually and additively associated with increased 5-year mortality risk, with similar PAFs in asymptomatic patients and those with symptomatic HF.
Authors: Alan S Go; Jingrong Yang; Lynn M Ackerson; Krista Lepper; Sean Robbins; Barry M Massie; Michael G Shlipak Journal: Circulation Date: 2006-06-05 Impact factor: 29.690
Authors: Robert J Mentz; Jacob P Kelly; Thomas G von Lueder; Adriaan A Voors; Carolyn S P Lam; Martin R Cowie; Keld Kjeldsen; Ewa A Jankowska; Dan Atar; Javed Butler; Mona Fiuzat; Faiez Zannad; Bertram Pitt; Christopher M O'Connor Journal: J Am Coll Cardiol Date: 2014-11-24 Impact factor: 24.094
Authors: Janani Rangaswami; Vivek Bhalla; John E A Blair; Tara I Chang; Salvatore Costa; Krista L Lentine; Edgar V Lerma; Kenechukwu Mezue; Mark Molitch; Wilfried Mullens; Claudio Ronco; W H Wilson Tang; Peter A McCullough Journal: Circulation Date: 2019-04-16 Impact factor: 29.690
Authors: Theresa A McDonagh; Marco Metra; Marianna Adamo; Roy S Gardner; Andreas Baumbach; Michael Böhm; Haran Burri; Javed Butler; Jelena Čelutkienė; Ovidiu Chioncel; John G F Cleland; Andrew J S Coats; Maria G Crespo-Leiro; Dimitrios Farmakis; Martine Gilard; Stephane Heymans; Arno W Hoes; Tiny Jaarsma; Ewa A Jankowska; Mitja Lainscak; Carolyn S P Lam; Alexander R Lyon; John J V McMurray; Alexandre Mebazaa; Richard Mindham; Claudio Muneretto; Massimo Francesco Piepoli; Susanna Price; Giuseppe M C Rosano; Frank Ruschitzka; Anne Kathrine Skibelund Journal: Eur Heart J Date: 2021-09-21 Impact factor: 29.983
Authors: Joerg C Schefold; Gerasimos Filippatos; Gerd Hasenfuss; Stefan D Anker; Stephan von Haehling Journal: Nat Rev Nephrol Date: 2016-08-30 Impact factor: 28.314
Authors: Ken J Lu; Leighton G Kearney; David L Hare; Michelle Ord; Deidre Toia; Elizabeth Jones; Louise M Burrell; Piyush M Srivastava Journal: Am J Cardiol Date: 2013-01-30 Impact factor: 2.778
Authors: Hessel F Groenveld; James L Januzzi; Kevin Damman; Jan van Wijngaarden; Hans L Hillege; Dirk J van Veldhuisen; Peter van der Meer Journal: J Am Coll Cardiol Date: 2008-09-02 Impact factor: 24.094